MED Alliance International, a division of MED Alliance Group, LLC, is excited to partner with IMBiotechnologies, the manufacturer of Ekobi ™ Microspheres used in therapeutic embolization. Ekobi Microspheres are a first-in-class biodegradable embolic agent, detectable by ultrasound, and effective in the treatment of unresectable/inoperable hypervascularized tumors.

A Canadian-based company, IMB is partnering with MED Alliance to provide logistical and operational support to distribute Ekobi to U.S. clinical customers.

“MED Alliance International’s dedication to ISO certification and our strong relationships with U.S. hospitals can benefit companies like IMB who are working toward expanding their market share in the U.S. and Canada,” said MED Alliance Vice President of Operations Lindsey Allende. “We take the guesswork out of the equation, eliminate barriers and provide channels to help our partners grow.”

IMB’s mission is to create and commercialize innovative products that treat human disease and improve quality of life. Their core technology helps in the treatment of conditions such as liver and kidney cancer, uterine fibroids and enlarged prostates.

“Ekobi Microspheres are delivered through a catheter into the blood vessels that feed a target tissue and selectively block the tissue’s blood supply,” said IMB Director of Marketing and Business Development Kelly Mottet. “Our product is the first and only biodegradable embolic agent detectable by ultrasound.”

Unlike other embolic agents, Ekobi Microspheres are detectable by ultrasound during and after the procedure and safely break down into carbon dioxide and water in 4-6 months.

Learn more about Ekobi Microspheres.

MED Alliance International is an ISO 13485 certified medical device distributor offering domestic and foreign medical device manufacturers specialized logistical and operational solutions. We are dedicated to partnering with manufacturers of high quality, cost-effective and innovative medical devices that improve patient care. We are delighted to add IMBiotechnologies to our portfolio of manufacturing partners.